Related Experiment Video
Updated: Aug 24, 2026
A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels
Published on: April 24, 2012
Differential desensitization of somatostatin receptor subtypes in atT-20 cells
Fredric C Mazza1, Allan D Blake
1Department of Biology, Seton Hall University, South Orange, NJ 07079, USA.
Abstract:
Nonpeptidyl agonists for the somatostatin (SRIF) receptor family have been developed. We have studied the desensitization effects for two of these agonists upon SRIF receptor function in AtT-20 cells, a neuroendocrine tumor cell, which endogenously expresses two distinct SRIF receptor, subtypes. We observe that SRIF and the nonpeptidyl, subtype selective agonists, differentially regulate SRIF receptor subtypes in the AtT-20 cell.
Insights
New nonpeptidyl agonists targeting somatostatin (SRIF) receptors show differential desensitization effects. These selective agonists differentially regulate SRIF receptor subtypes in neuroendocrine tumor cells.
Area of Science:
- Endocrinology
- Neuroendocrinology
- Pharmacology
Background:
- Nonpeptidyl agonists targeting the somatostatin (SRIF) receptor family have been developed.
- AtT-20 cells, a neuroendocrine tumor cell line, endogenously express two distinct SRIF receptor subtypes.
Purpose of the Study:
- To investigate the desensitization effects of two nonpeptidyl agonists on SRIF receptor function.
- To compare the regulatory effects of SRIF and nonpeptidyl agonists on SRIF receptor subtypes in AtT-20 cells.
Main Methods:
- Utilized AtT-20 cells expressing two endogenous SRIF receptor subtypes.
- Studied the desensitization effects of nonpeptidyl agonists on SRIF receptor function.
Main Results:
- Somatostatin (SRIF) and the nonpeptidyl agonists demonstrated differential regulation of SRIF receptor subtypes.
- Observed distinct desensitization patterns for the studied agonists.
Conclusions:
- Nonpeptidyl SRIF receptor agonists exhibit differential regulation of receptor subtypes.
- These findings contribute to understanding the pharmacology of novel SRIF receptor modulators.
